These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7865698)

  • 1. Resistance to activated protein C is reduced in women using oral contraceptives.
    Osterud B; Robertsen R; Asvang GB; Thijssen F
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):853-4. PubMed ID: 7865698
    [No Abstract]   [Full Text] [Related]  

  • 2. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral contraceptives on hemostasis and thrombosis.
    Rosing J; Tans G
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of activated protein C resistance in stored plasma.
    Girolami A; Simioni P; Scarano L
    Lancet; 1994 May; 343(8908):1288-90. PubMed ID: 7910292
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral contraceptives and venous thromboembolism.
    Szarewski A; Hollingworth B; Mansour D; Hampton N; Walling M
    Lancet; 1997 May; 349(9065):1622. PubMed ID: 9174575
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral contraceptives and venous thromboembolism.
    Lewis MA; Heinemann LA
    Lancet; 1997 May; 349(9065):1621-2. PubMed ID: 9174574
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
    Bennet L; Odeberg H
    J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptives and venous thromboembolism.
    Lowe GD; Rumley A; Woodward M; Reid E
    Lancet; 1997 May; 349(9065):1623. PubMed ID: 9174576
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased resistance to activated protein C in women taking third-generation oral contraceptives?
    Gris JC; Nouvellon-Cochery E; Marès P
    Blood; 2004 Sep; 104(6):1907; author reply 1908-9. PubMed ID: 15342364
    [No Abstract]   [Full Text] [Related]  

  • 11. Sensitivity to activated protein C; influence of oral contraceptives and sex.
    Henkens CM; Bom VJ; Seinen AJ; van der Meer J
    Thromb Haemost; 1995 Mar; 73(3):402-4. PubMed ID: 7667823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives.
    Hellgren M; Svensson PJ; Dahlbäck B
    Am J Obstet Gynecol; 1995 Jul; 173(1):210-3. PubMed ID: 7631684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral venous thrombosis and activated protein C resistance.
    Dulli DA; Luzzio CC; Williams EC; Schutta HS
    Stroke; 1996 Oct; 27(10):1731-3. PubMed ID: 8841319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
    van Vliet HA; Frolich M; Christella M; Thomassen LG; Doggen CJ; Rosendaal FR; Rosing J; Helmerhorst FM
    Hum Reprod; 2005 Feb; 20(2):563-8. PubMed ID: 15539435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptives and venous thromboembolism: acquired APC resistance?
    Schramm W; Heinemann LA
    Br J Haematol; 1997 Aug; 98(2):491-2. PubMed ID: 9266957
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of factor V Leiden, oral contraceptive use, type of oral contraceptives and pregnancy on APC-r levels in women with or without a history of pre-eclampsia.
    Bloemenkamp KW; de Groot CJ; Ronde HD; Duvekot EJ; Helmerhorst FM; Bertina RM
    Eur J Obstet Gynecol Reprod Biol; 2001 Apr; 95(2):225. PubMed ID: 11301177
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public health approach to activated protein C resistance assay.
    Poka R; Ajzner E; Balogh I
    Am J Obstet Gynecol; 1997 Nov; 177(5):1271-2. PubMed ID: 9396930
    [No Abstract]   [Full Text] [Related]  

  • 19. [APC resistance, oral contraceptives and thrombosis. Screening is justified for diagnosing high-risk cases].
    Dahlbäck B
    Lakartidningen; 1997 Apr; 94(16):1522-4. PubMed ID: 9173200
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins.
    Olivieri O; Friso S; Manzato F; Grazioli S; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C; Corrocher R
    Contraception; 1996 Sep; 54(3):149-52. PubMed ID: 8899255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.